0
Original Research: COPD |

Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD*

Denis E. O’Donnell, MD; Frank Sciurba, MD; Bartolome Celli, MD; Donald A. Mahler, MD; Katherine A. Webb; Chris J. Kalberg, PhD; Katharine Knobil, MD
Author and Funding Information

*From Queen’s University (Dr. O’Donnell and Ms. Webb), Kingston, ON, Canada; University of Pittsburgh (Dr. Sciurba), Pittsburgh, PA; Caritas St. Elizabeth’s Medical Center (Dr. Celli), Tufts University School of Medicine, Boston, MA; Dartmouth Hitchcock Medical Center (Dr. Mahler), Lebanon, NH; and GlaxoSmithKline (Dr. Kalberg and Dr. Knobil), Research Triangle Park, NC.

Correspondence to: Denis E. O’Donnell, MD, 102 Stuart St, Kingston, ON, Canada K7L 2V6; e-mail: odonnell@post.queensu.ca



Chest. 2006;130(3):647-656. doi:10.1378/chest.130.3.647
Text Size: A A A
Published online

Study objective: To examine the effect of fluticasone propionate, 250 μg/salmeterol, 50 μg combination (FSC 250/50) twice daily on lung hyperinflation and associated measures of exercise performance in patients with COPD.

Design: This was a randomized, double-blind, parallel-group study.

Patients: Eligible patients were ≥ 40 years old with a diagnosis of COPD, prealbuterol FEV1 < 70% of predicted, FEV1/FVC ratio ≤ 0.70, and functional residual capacity (FRC) ≥ 120% of predicted normal.

Interventions: Patients were randomized to FSC 250/50; salmeterol, 50 μg; or placebo twice daily for 8 weeks. Predose and postdose spirometry, plethysmography, and constant-load cycle cardiopulmonary exercise test evaluations were compared. The primary comparison was FSC 250/50 with placebo. The salmeterol group was included for exploratory comparisons with FSC 250/50.

Results: A total of 185 patients (mean baseline FEV1 of 41% predicted) were enrolled. At rest, FSC 250/50 significantly reduced postdose FRC and increased inspiratory capacity (IC) compared with placebo (differences of − 0.35 ± 0.12 L and 0.33 ± 0.06 L [mean ± SE], respectively, at week 8; p ≤ 0.003) and increased exercise endurance time (difference, 132 ± 45 s; p = 0.004). At a standardized time during exercise (isotime), FSC 250/50 increased postdose IC by 0.20 ± 0.05 L over placebo with associated improvements in tidal volume and minute ventilation (p < 0.05 vs placebo at week 8). Improvement in exercise time was significantly correlated with the increase in IC (r = 0.45, p < 0.001) but not FEV1 (r = 0.23, p = 0.08). Predose comparisons of FSC 250/50 with salmeterol and placebo favored FSC 250/50.

Conclusion: We conclude that FSC 250/50 decreases lung hyperinflation at rest and during exercise with an associated increase in exercise endurance time when compared with placebo.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543